Otonomy, Inc. is a biopharmaceutical company. The company has market cap of $378.17 million. The Firm focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It currently has negative earnings. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311.
Analysts expect Encana Corp (TSE:ECA) to report $0.10 EPS on May, 2.They anticipate $0.31 EPS change or 147.62% from last quarter’s $-0.21 EPS. T_ECA’s profit would be $94.07 million giving it 37.55 P/E if the $0.10 EPS is correct. After having $0.12 EPS previously, Encana Corp’s analysts see -16.67% EPS growth. About 1.26M shares traded. Encana Corp (TSE:ECA) has risen 17.72% since September 13, 2016 and is uptrending. It has outperformed by 7.79% the S&P500.
Since January 1, 0001, it had 0 insider buys, and 1 sale for $192,006 activity.
About 37,397 shares traded. Otonomy Inc (NASDAQ:OTIC) has declined 31.19% since September 13, 2016 and is downtrending. It has underperformed by 41.12% the S&P500.
Amici Capital Llc holds 1.47% of its portfolio in Otonomy Inc for 237,885 shares. Harvey Capital Management Inc owns 127,725 shares or 0.95% of their US portfolio. Moreover, Kingdon Capital Management L.L.C. has 0.46% invested in the company for 604,860 shares. The New York-based Orbimed Advisors Llc has invested 0.37% in the stock. Tpg Group Holdings (Sbs) Advisors Inc., a Texas-based fund reported 2.16 million shares.
Ratings analysis reveals 100% of Otonomy’s analysts are positive. Out of 2 Wall Street analysts rating Otonomy, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. OTIC was included in 3 notes of analysts from August 10, 2015. Bernstein upgraded the stock to “Outperform” rating in Monday, August 10 report. The rating was initiated by JP Morgan with “Hold” on Thursday, August 13. The rating was initiated by WallachBeth Capital on Thursday, May 26 with “Buy”.
Analysts await Otonomy Inc (NASDAQ:OTIC) to report earnings on May, 8. They expect $-0.88 EPS, up 3.30% or $0.03 from last year’s $-0.91 per share. After $-0.88 actual EPS reported by Otonomy Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
